| Business Summary | | VIVUS,
Inc.
is
a
pharmaceutical
company
engaged
in
developing,
acquiring
and
marketing
products
to
improve
quality-of-life
disorders
in
men
and
women,
with
a
focus
on
sexual
dysfunction.
The
Company
developed
and
markets
in
the
United
States,
Muse
(alprostadil)
and
Actis,
two
treatments
of
erectile
dysfunction
(ED).
VIVUS
has
ongoing
research
and
development
programs
in
male
ED,
female
sexual
dysfunction
(FSD)
and
male
premature
ejaculation.
Adding
to
the
Company's
research
and
development
pipeline
in
the
first
quarter
of
2001,
VIVUS
licensed
from
Tanabe
Seiyaku
Co.,
Ltd.,
the
proprietary
phosphodiesterase
type
five
inhibitor
compound,
TA-1790,
for
the
oral
and
local
treatment
of
male
and
female
sexual
dysfunction.
In
January
2001,
the
Company
began
enrolling
patients
in
a
multi-center
clinical
study
for
its
FSD
product,
Alista,
intended
to
evaluate
the
sexual
response
in
women
with
a
primary
diagnosis
of
Female
Sexual
Arousal
Disorder. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VIVUS,
Inc.
focuses
on
the
design
and
development
of
products
for
the
treatment
of
erectile
dysfunction
whose
products
include
MUSE
(alprostadil)
and
ACTIS.
For
the
six
months
ended
6/30/01,
sales
decreased
10%
to
$12.7
million.
Net
loss
totaled
$5.8
million
vs.
an
income
of
$2.4
million.
Revenues
reflect
lower
MUSE
prescriptions
and
termination
of
the
Company's
distribution
agreement
with
AstraZeneca.
Net
loss
reflects
a
$5
million
payment
for
the
licensing
of
the
TA-1790
compound. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Virgil Place, M.D., 76 Chairman
and CSO | -- | Leland Wilson, 56 Pres,
CEO | $378K | Richard Walliser, 57 CFO,
VP-Fin. | 171K | Neil Gesundheit, M.D., 48 VP-
Clinical Research and CMO | -- | Carol Karp, 48 VP-
Regulatory Affairs and Project Management | 185K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|